Par Pharmaceutical Companies has entered into a definitive agreement to acquire Anchen Pharmaceuticals, a privately-held specialty pharmaceutical company, for $410 million in cash. Anchen develops and commercializes extended release and niche generic products. Anchen has five commercialized products, 27 ANDAs on file with the FDA, and approximately 26 additional products in development. Anchen anticipates launching eight to 10 generic products during the next two years. Headquartered in Irvine, ...